Compare Stocks

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX BriaCell Therapeutics	$2.02 -6.0%	$2.94	$2.01 ▼ $7.59	$32.28M	1.02	92,731 shs	41,367 shs
COT Cotinga Pharmaceuticals Inc. (COT.V)	C$0.04 -41.7%	C$0.03	C$0.02 ▼ C$0.12	C$770K	N/A	20,281 shs	1,000 shs
MTFB MOTIF BIO PLC/S	$0.11	$0.10	$0.08 ▼ $11.50	N/A	N/A	N/A	867,698 shs
RVV Revive Therapeutics	C$0.08 +14.3%	C$0.08	C$0.07 ▼ C$0.25	C$5.79M	N/A	93,085 shs	212,852 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX BriaCell Therapeutics	-5.61%	-18.88%	-10.62%	-51.33%	-71.94%
COT Cotinga Pharmaceuticals Inc. (COT.V)	0.00%	0.00%	0.00%	0.00%	0.00%
MTFB MOTIF BIO PLC/S	0.00%	0.00%	0.00%	0.00%	0.00%
RVV Revive Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCTX BriaCell Therapeutics	1.5486 of 5 stars	3.5	4.0	0.0	0.0	0.6	1.7	0.0
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCTX BriaCell Therapeutics	3.00	Buy	$18.00	791.09% Upside
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCTX BriaCell Therapeutics	N/A	N/A	N/A	N/A	($0.24) per share	N/A
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	N/A	C$0.00 per share	17.50	C($0.18) per share	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	C$0.03 per share	3.18	C$0.02 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCTX BriaCell Therapeutics	-$20.30M	-$1.68	N/A	N/A	N/A	N/A	N/A	-57.48%	6/12/2024 (Estimated)
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	-C$0.12	N/A	∞	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	-C$0.02	N/A	∞	N/A	N/A	N/A	N/A	6/4/2024 (Estimated)

Latest BCTX, MTFB, SALV, COT, and RVV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/18/2024	Q2 2024	BCTX BriaCell Therapeutics	-$0.20	-$0.71	-$0.51	-$0.71	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCTX BriaCell Therapeutics	N/A	N/A	N/A	N/A	N/A
COT Cotinga Pharmaceuticals Inc. (COT.V)	C$0.24	685.71%	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCTX BriaCell Therapeutics	N/A	2.99	2.99
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	0.05	0.01
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A
RVV Revive Therapeutics	N/A	6.14	6.03

Ownership

Institutional Ownership

Company	Institutional Ownership
BCTX BriaCell Therapeutics	15.42%
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A
MTFB MOTIF BIO PLC/S	N/A
RVV Revive Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BCTX BriaCell Therapeutics	21.77%
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A
MTFB MOTIF BIO PLC/S	N/A
RVV Revive Therapeutics	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BCTX BriaCell Therapeutics	16	15.98 million	12.50 million	Optionable
COT Cotinga Pharmaceuticals Inc. (COT.V)	N/A	21.99 million	N/A	Not Optionable
MTFB MOTIF BIO PLC/S	7	N/A	N/A	Not Optionable
RVV Revive Therapeutics	N/A	72.41 million	N/A	Not Optionable

BCTX, MTFB, SALV, COT, and RVV Headlines

Source	Headline
	Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product markets.businessinsider.com - April 18 at 8:03 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID finanznachrichten.de - March 27 at 4:23 PM
	Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID finance.yahoo.com - March 27 at 10:10 AM
	Revive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID finanznachrichten.de - March 19 at 11:42 AM
	Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID markets.businessinsider.com - March 19 at 11:42 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Update finanznachrichten.de - March 12 at 8:23 AM
	Revive Therapeutics Provides Corporate Update financialpost.com - March 12 at 7:08 AM
	Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 markets.businessinsider.com - February 26 at 8:53 PM
	Revive Therapeutics Explores the Use of Bucillamine for Long COVID markets.businessinsider.com - February 1 at 9:20 AM
	Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500 markets.businessinsider.com - January 31 at 7:29 PM
	Revive Therapeutics Ltd. Announces Offering of Up to $3 Million financialpost.com - January 24 at 7:03 PM
	Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada tmcnet.com - January 16 at 8:29 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine finanznachrichten.de - January 10 at 2:05 PM
	Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine markets.businessinsider.com - January 10 at 9:05 AM
	Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40M msn.com - January 8 at 4:03 PM
	Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders markets.businessinsider.com - December 20 at 5:50 PM
	Revive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of Bucillamine markets.businessinsider.com - December 18 at 8:03 AM
	Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine financialpost.com - December 18 at 7:07 AM
	Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure markets.businessinsider.com - October 17 at 4:48 PM
	Revive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent Exposure markets.businessinsider.com - October 17 at 11:47 AM
	Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development finanznachrichten.de - October 11 at 2:48 PM
	Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development tmcnet.com - October 11 at 9:47 AM
	Revive I-5 project continues with driving surface improvement work starting Monday komonews.com - October 11 at 12:00 AM
	Italy turns to Kyrgyz shepherds to revive Sardinian farming ft.com - September 28 at 9:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BriaCell Therapeutics

NASDAQ:BCTX

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Cotinga Pharmaceuticals Inc. (COT.V)

CVE:COT

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

MOTIF BIO PLC/S

NASDAQ:MTFB

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Revive Therapeutics

CVE:RVV

Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial